Kits, methods and applications for inducing pluripotent stem cell differentiation into hepatocytes
By using a composite crystal scaffold synergistically with small molecules ITE and SR12813 to induce a differentiation system, the problem of immature hepatocyte differentiation in existing technologies has been solved, achieving efficient three-dimensional culture of functional hepatocytes and improving hepatocyte maturity and drug metabolism capacity.
Patent Information
- Application Number
- CN202611624282.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-20
- Publication Date
- 2026-11-17
AI Technical Summary
Existing hepatocyte culture and iPSC directed differentiation systems cannot replicate the complex microenvironment of human development, resulting in iPSC-differentiated cells often remaining in an immature precursor state with unsatisfactory differentiation effects and low CYP enzyme activity levels, which severely restricts the physiological relevance and clinical reliability of in vitro culture systems.
An induction system employing a composite crystalline gel scaffold synergistically with small molecules ITE and SR12813 was used to promote the differentiation of hepatocytes into mature hepatocytes by simulating the embryonic liver development process and combining staged chemical induction with a three-dimensional culture microenvironment.
It significantly improved the maturity and function of hepatocytes, especially the expression and activity of drug metabolism-related enzymes, enhanced the drug metabolism capacity of hepatocytes, made them closer to natural mature hepatocytes, and improved the biological function and phenotypic stability of hepatocytes.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention relates to the field of cell engineering technology, and in particular to kits, methods and applications for inducing pluripotent stem cells to differentiate into hepatocytes. Background Technology
[0002] The liver is a core organ for maintaining metabolic homeostasis in the human body, playing an irreplaceable and crucial role in physiological processes such as nutrient metabolism, energy supply, toxin removal, and substance synthesis and storage. Currently, liver transplantation remains the only effective treatment for end-stage liver disease, but its widespread application is fundamentally limited by a severe shortage of donor livers, high surgical risks, and immune rejection. Bioartificial liver support systems constructed using in vitro cultured hepatocytes can provide transitional treatment for patients with liver failure, demonstrating significant clinical value in waiting for liver transplantation or promoting autologous liver tissue regeneration.
[0003] In recent years, the directed differentiation of human pluripotent induced stem cells (iPSCs) into functional hepatocyte-like cells (HLCs) has become an important development direction in the fields of liver regenerative medicine and cell therapy. Compared with primary hepatocytes, iPSCs have advantages such as wide availability, unlimited expansion, and ease of gene editing, and are expected to provide a large-scale, standardized cell source for the construction of in vitro liver disease models, drug toxicity screening, and cell replacement therapy.
[0004] However, existing hepatocyte culture and iPSC-directed differentiation systems still have significant technical limitations. Traditional culture methods cannot replicate the complex microenvironment of human development, resulting in iPSC-differentiated cells often remaining in an immature precursor state, leading to unsatisfactory differentiation outcomes. Furthermore, the low CYP enzyme activity levels in hepatocytes differentiated from iPSCs severely restrict the physiological relevance and clinical reliability of in vitro culture systems.
[0005] Therefore, developing a culture system that can induce pluripotent stem cells to differentiate into functional hepatocytes has become a key technical problem that urgently needs to be solved. Summary of the Invention
[0006] The purpose of this invention is to address the aforementioned shortcomings of the prior art by providing a kit, method, and application for inducing pluripotent stem cells to differentiate into hepatocytes, thereby overcoming the deficiency that iPSCs often produce immature precursor cells and have unsatisfactory differentiation effects in practical applications.
[0007] To achieve the above objectives, the present invention adopts the following technical solution: A first aspect of the present invention is to provide a kit for inducing pluripotent stem cells to differentiate into hepatocytes, the kit comprising: A composite crystal scaffold assembly is used to provide a porous framework for the attachment and growth of hepatocytes. The porous material is cast onto a fabric, and after a freeze cross-linking reaction, an ice crystal template is formed. The ice crystal template is then removed by freeze drying. The fabric has a pore size of 1~500 µm and a thickness of 0.5~3 mm. The preparation process of the porous material is as follows: The molding materials were dissolved in water to obtain hyaluronic acid solution, sodium alginate solution, and gelatin solution with a mass-volume concentration of 1% to 3%; A premixed solution was obtained by mixing the ingredients in a preset volume ratio of 1:(0.5~1.5):(0.5~1.5). Then, a crosslinking agent was added to the premixed solution and stirred until homogeneous to obtain a mixed solution with a total solid content of 0.5%~20.0%, which is the porous material. The crosslinking agent is a mixture of NHS and EDC. The chemical induction assembly comprises the following modules, packaged independently in sequence according to differentiation time: Endoderm induction module, used to induce pluripotent stem cells into endoderm cells; The hepatoblast differentiation module is used to differentiate endoderm cells into hepatoblasts; A hepatoblast maturation induction module for differentiating hepatoblasts into mature hepatocytes, the hepatoblast maturation induction module comprising small molecule ITE and SR12813; The composite crystal scaffold assembly is used in conjunction with the hepatoblast maturation induction module to seed the hepatoblasts into the composite crystal scaffold assembly, which provides three-dimensional support for the hepatoblasts.
[0008] Furthermore, the endoderm induction module includes a first culture medium and a second culture medium. The first culture medium contains a first basal culture medium, B27 minus insulin, GlutaMax, Activin A, and Wnt3a; the second culture medium contains a second basal culture medium, GlutaMax, B27, vitamin C, and KGF.
[0009] Furthermore, the hepatoblast differentiation module includes a third culture medium, which contains a third basal culture medium, Glutamax, B27, NEAA, FGF2, and BMP4.
[0010] Furthermore, the hepatocyte maturation induction module includes a fourth culture medium containing hepatocyte basal culture medium, dexamethasone, DAPT, Forskolin, insulin, ascorbic acid, ITE, and SR12813.
[0011] Furthermore, the concentration of ITE in the fourth culture medium is 0.2~0.6 µM, and the concentration of SR12813 is 0.5~1.2 µM.
[0012] Furthermore, the first basal culture medium, the second basal culture medium, and the third basal culture medium are all at least one of DMEM high glucose, DMEM-F12, and RPMI1640 culture medium.
[0013] Further, the first culture medium is based on RPMI1640 and contains 0.5-1.5% (v / v) B27minus insulin, 0.5-1.5% (v / v) GlutaMax, 80-120 ng / mL Activin A and 40-60 ng / mL Wnt3a; the second culture medium is based on RPMI1640 and contains 0.5-1.5% (v / v) GlutaMax, 0.5-1.5% (v / v) B27, 5-15 μg / ml vitamin C and 45-55 ng / ml KGF.
[0014] Furthermore, the third culture medium is based on RPMI1640 and contains 0.5-1.5% (v / v) Glutamax, 0.5-1.5% (v / v) B27, 0.5-1.5% (v / v) NEAA, 5-15 μg / ml FGF2 and 15-25 ng / ml BMP4.
[0015] Furthermore, the fourth culture medium uses hepatocyte basal medium as a matrix and contains 8-12 µM dexamethasone, 5-15 µM DAPT, 5-15 µM Forskolin, 5-15 µg / mL insulin, 0.5-1.5 mM ascorbic acid, 0.2-0.6 µM ITE, and 0.5-1.2 µM SR12813.
[0016] Furthermore, the concentration of NHS in the mixed solution is 1 mg / mL to 2 mg / mL, and the concentration of EDC is 3 mg / mL to 4 mg / mL.
[0017] Furthermore, the fabric is one of non-cytotoxic needle-punched cotton, non-woven fabric, and hot-air cotton.
[0018] Furthermore, the reaction temperature of the freeze crosslinking reaction is -25°C to -10°C, and the reaction time is 12 to 48 hours; Furthermore, the vacuum degree of the freeze drying is 0.06~0.08 MPa, the cold trap temperature is -60℃ to -40℃, and the drying time is 8~48 h.
[0019] Furthermore, the composite crystal scaffold is used as a culture material for three-dimensional cell spheres.
[0020] A second aspect of the present invention is to provide the use of the above-described kit in the preparation of hepatocyte organoid products.
[0021] A third aspect of the present invention is to provide a method for in vitro induction of pluripotent stem cells to differentiate into hepatocytes, comprising the following steps: Pluripotent stem cells were cultured in the first culture medium for 2.5–3.5 days and in the second culture medium for 1.5–2.5 days to obtain endoderm cells; Endoderm cells were cultured in the third culture medium for 4.5–5.5 days to obtain hepatocytes; Hepatocytes were obtained by culturing hepatoblasts in the fourth culture medium for 11–13 days.
[0022] A fourth aspect of the present invention is to provide the use of hepatocytes obtained by the method of in vitro induced differentiation of pluripotent stem cells into hepatocytes in the preparation of hepatocyte transplantation products, bioartificial livers or microencapsulated hepatocyte preparations.
[0023] Compared with the prior art, the beneficial effects of the present invention are: (1) The combined application of small molecule ITE and SR12813 provided by the present invention can promote the differentiation of hepatocytes into mature hepatocytes. The combined application of the two can improve the maturity of the induced hepatocytes and promote the establishment of hepatocyte metabolism-related functions. In particular, the combined application of small molecule ITE and SR12813 can improve the expression and activity of drug metabolism-related enzymes, including cytochrome P450 family enzymes and other metabolic enzymes, thereby enhancing the drug metabolism capacity of induced hepatocytes, improving the functional maturity of the obtained hepatocytes, and making them closer to natural mature hepatocytes.
[0024] (2) The composite crystalloid scaffold provided by the present invention can promote hepatocyte maturation and maintain hepatocyte phenotype. Compared with the traditional monolayer planar culture system, the expression levels of hepatocyte maturation-related functions such as ALB, HNF4α and drug-metabolizing enzyme CYP3A4 are significantly increased in hepatocytes induced by the composite crystalloid scaffold, indicating that the composite crystalloid scaffold is beneficial to promoting hepatocyte functional maturation and metabolic function formation. The expression of the mesenchymal transformation-related marker gene Vimentin is reduced, indicating that the composite crystalloid scaffold is beneficial to maintaining hepatocyte epithelial characteristics, inhibiting cell transformation to mesenchymal phenotype, reducing cell functional degradation during induction, and improving the phenotypic stability of induced hepatocytes.
[0025] (3) The composite crystalloid scaffold provided by this invention works synergistically with small molecule ITE and SR12813 to promote the formation of hepatocyte function, and can simultaneously achieve cell microenvironment regulation and maturation signal regulation. The composite crystalloid scaffold is beneficial to maintaining cell polarity and intercellular interactions, while small molecule ITE and small molecule SR12813 promote the establishment of maturation-related metabolic functions. The combined application of the two is beneficial to promoting the expression of hepatocyte maturation-related functional proteins and drug-metabolizing enzymes, and improving the induced biological function and maturation degree of hepatocytes.
[0026] (4) The composite crystal scaffold provided by the present invention is combined with the induction system of small molecule ITE and SR12813, so that the obtained hepatocytes are closer to natural mature hepatocytes in terms of molecular characteristics and functional properties, providing a new technical solution for the standardized preparation of organoids or hepatocyte spheres derived from pluripotent stem cells. Attached Figure Description
[0027] Figure 1 This is a graph showing the detection of CYP450 enzyme activity in cells in Example 1; Figure 2 This is a diagram showing the detection of expression of metabolic genes related to phase I and phase II by RT-qPCR in Example 1; Figure 3 Image showing hepatocyte staining on composite crystalloid scaffold 1; Figure 4 Image showing hepatocyte staining on composite crystalloid scaffold 2; Figure 5 Image showing hepatocyte staining on composite crystalloid scaffold 3; Figure 6 Image showing hepatocyte staining on composite crystalloid scaffold 4; Figure 7 The image shows a scanning electron microscope (SEM) image of the composite crystal scaffold 3. Figure 8 The results of double staining of live and dead hepatocytes on the composite crystalloid scaffold in Example 4; Figure 9 Image showing the results of Western bolt culture of liver-like cells in a single-layer two-dimensional culture and a composite crystal gel scaffold. Figure 10 Figure 1 shows the results of gene transcription level detection in liver-like cells cultured in a single-layer two-dimensional culture and a composite crystal gel scaffold. Figure 11 ALB immunofluorescence staining image of liver-like cells cultured on a single-layer two-dimensional culture scaffold and a composite crystal gel scaffold. Figure 12 AAT immunofluorescence staining image of liver-like cells cultured on a single-layer two-dimensional culture scaffold and a composite crystal gel scaffold. Figure 13 Immunofluorescence staining of CYP3A4 in liver-like cells cultured on a monolayer two-dimensional culture scaffold and a composite crystalloid scaffold. Figure 14 Immunofluorescence staining of CPS1 in liver-like cells cultured in a monolayer two-dimensional culture and a composite crystalloid scaffold; Figure 15 Image showing Vinmentin immunofluorescence staining of liver-like cells cultured in a single-layer two-dimensional culture and a composite crystal gel scaffold. Detailed Implementation
[0028] To make the objectives, technical solutions, and advantages of this invention clearer, the specific embodiments and accompanying drawings are described in further detail below. Where specific techniques or conditions are not specified in the embodiments, they are performed according to the techniques or conditions described in the literature in this field or according to the product instructions. Reagents or instruments whose manufacturers are not specified are all commercially available conventional products.
[0029] This invention provides a kit for inducing pluripotent stem cells to differentiate into hepatocytes, the kit comprising: A composite crystalline gel scaffold assembly is used to provide a porous framework for the attachment and growth of hepatocytes. It consists of a porous material loaded onto a fabric substrate to form a three-dimensional culture structure. The fabric substrate can be one of non-cytotoxic needle-punched cotton, non-woven fabric, or hot-air cotton. The porous material is prepared by mixing a molding material and a crosslinking agent. The molding material is a mixture of sodium alginate, gelatin, and hyaluronic acid, and the crosslinking agent is a mixture of NHS and EDC. Preferably, the porous material is uniformly distributed on the surface and within the pores of the fabric, forming a three-dimensional network structure. The overall pore size ranges from 1 to 150 µm, and the porosity is 85% to 95%. The pore size of the fabric is 1 to 500 µm, and the thickness is 0.5 to 3 mm. The chemical induction assembly comprises the following modules, packaged independently in sequence according to differentiation time: An endoderm induction module is used to induce pluripotent stem cells into endoderm cells; the endoderm induction module includes a first culture medium and a second culture medium, the first culture medium containing a first basal culture medium, B27 minus insulin, GlutaMax, Activin A and Wnt3a; the second culture medium containing a second basal culture medium, GlutaMax, B27, vitamin C and KGF. Preferably, both the first and second basal media are selected from DMEM high glucose, DMEM-F12, and RPMI1640 media; the first media is based on RPMI1640 and contains 0.5-1.5% (v / v) B27 minus insulin, 0.5-1.5% (v / v) GlutaMax, 80-120 ng / mL Activin A, and 40-60 ng / mL Wnt3a; the second media is based on RPMI1640 and contains 0.5-1.5% (v / v) GlutaMax, 0.5-1.5% (v / v) B27, 5-15 μg / ml vitamin C, and 45-55 ng / ml KGF.
[0030] A hepatoblast differentiation module is used to differentiate endoderm cells into hepatoblasts. The hepatoblast differentiation module includes a third culture medium comprising a third basal medium, Glutamax, B27, NEAA, FGF2, and BMP4. Preferably, the third basal medium is selected from DMEM high glucose, DMEM-F12, and RPMI 1640 media. The third culture medium uses RPMI 1640 as the basal medium and contains 0.5-1.5% (v / v) Glutamax, 0.5-1.5% (v / v) B27, 0.5-1.5% (v / v) NEAA, 5-15 μg / ml FGF2, and 15-25 ng / ml BMP4.
[0031] A hepatoblast maturation induction module is used to differentiate hepatoblasts into mature hepatocytes. The composite crystalloid scaffold assembly is used in conjunction with the hepatoblast maturation induction module to seed the hepatoblasts onto the composite crystalloid scaffold assembly, which provides three-dimensional support for the hepatoblasts.
[0032] The hepatocyte maturation induction module includes a fourth culture medium containing hepatocyte basal medium, dexamethasone, DAPT, Forskolin, insulin, ascorbic acid, ITE, and SR12813. Preferably, the fourth culture medium is based on BM medium and contains 8-12 µM dexamethasone, 5-15 µM DAPT, 5-15 µM Forskolin, 5-15 µg / mL insulin, 0.5-1.5 mM ascorbic acid, 0.2-0.6 µM ITE, and 0.5-1.2 µM SR12813.
[0033] This invention simulates the embryonic liver development process, achieving highly efficient and targeted differentiation of induced pluripotent stem cells into mature hepatocytes through a strategy of "three-dimensional microenvironment construction + staged chemical induction + synergistic regulation of maturation-promoting small molecules". Specifically, a composite crystalloid scaffold provides a three-dimensional extracellular microenvironment close to natural liver tissue. Endoderm-inducing components and hepatocyte differentiation components sequentially simulate different stages of embryonic development. The small molecules ITE and SR12813 in the hepatocyte maturation-inducing components synergistically regulate hepatocyte maturation and metabolic function, forming a related signaling network that promotes the transformation of hepatocytes into hepatocytes with mature drug metabolism capabilities and physiological functions, thereby obtaining highly mature and functional induced hepatocytes.
[0034] This invention also provides a method for preparing hepatocyte organoids using the above-mentioned kit. This method simulates the embryonic liver development process, achieving efficient and targeted differentiation of pluripotent stem cells into mature functional hepatocytes through a combination of staged chemical induction and a biomimetic three-dimensional culture microenvironment.
[0035] Specifically, pluripotent stem cells in good culture condition are seeded into a culture vessel. Once the cells reach a suitable growth state, an endoderm induction module is used to induce the pluripotent stem cells into endoderm cells. The process involves culturing in a first culture medium for 2.5–3.5 days, followed by culturing in a second culture medium for another 1.5–2.5 days, allowing the pluripotent stem cells to gradually differentiate into endoderm cells. During this induction process, the first and second culture media sequentially simulate the activation of relevant signaling pathways during embryonic development, laying the foundation for subsequent hepatic differentiation. After induction, the cells gradually lose their pluripotent stem cell morphology and acquire endoderm cell characteristics.
[0036] Subsequently, a hepatocyte differentiation module was used to differentiate endoderm cells into hepatocytes. Specifically, the resulting endoderm cells were cultured in a third culture medium for 4.5–5.5 days to further induce differentiation into hepatic progenitor cells and hepatocytes. The third culture medium can mimic the microenvironment of the hepatic bud formation stage during liver development, promoting the expression of hepatic lineage-related genes, enabling the cells to gradually acquire the hepatocyte phenotype and possess the potential for further maturation and differentiation.
[0037] After obtaining hepatoblasts, a hepatoblast maturation induction module was used to differentiate them into mature hepatocytes. Specifically, the hepatoblasts were seeded onto the composite crystalloid scaffold assembly, and cultured for 11-13 days using a fourth culture medium to allow further differentiation and maturation into hepatocytes. The fourth culture medium included a chemical induction system to promote hepatocyte maturation, containing specific small molecules ITE and SR12813. This invention found that the combined application of these two components can promote the establishment of hepatocyte maturation-related functions, increase the expression and activity of drug metabolism-related enzymes, thereby enhancing the metabolic function and biological activity of induced hepatocytes. The biomimetic three-dimensional culture microenvironment constructed by the composite crystalloid scaffold, combined with the maturation induction system containing specific small molecules ITE and SR12813, can achieve joint regulation of physical microenvironment and chemical signal regulation. Specifically, the composite crystalloid scaffold helps maintain cell polarity, promotes intercellular interactions and tissue-like structure formation, while the specific small molecules ITE and SR12813 further promote hepatocyte maturation and functional establishment. The combined effect of these two components improves the maturity and functional stability of the induced hepatocytes.
[0038] Experimental results showed that, compared with hepatocytes induced by the traditional monolayer planar culture system, the expression levels of mature hepatocyte-related functional proteins ALB, HNF4α, and drug-metabolizing enzyme CYP3A4 were significantly increased in hepatocytes obtained using the method of this invention, while the expression level of the EMT-related marker gene Vimentin was significantly decreased. This indicates that the composite crystalloid scaffold constructed in this invention can not only promote the functional maturation of hepatocytes but also help maintain the hepatocyte epithelial phenotype, inhibit the tendency of interstitial cell formation, and improve the phenotypic stability and functional integrity of induced hepatocytes.
[0039] This invention differs from existing two-dimensional culture induction strategies. Instead, it introduces a composite crystalloid scaffold to construct a biomimetic three-dimensional microenvironment at the hepatocyte stage. Combined with a maturation induction system containing specific small molecules ITE and SR12813, it achieves temporal regulation of hepatocyte microenvironment remodeling and functional maturation. This results in induced hepatocytes with high maturity, strong drug metabolism capacity, and a stable epithelial phenotype. The expression of maturation markers such as ALB, HNF4α, and CYP3A4 is significantly increased, while the expression of the EMT-related gene Vimentin is decreased. This yields induced hepatocytes that more closely resemble the biological characteristics of naturally mature hepatocytes. EMT (Epithelial-Mesenchymal Transition) refers to the reversible biological process by which epithelial cells transform into a mesenchymal cell phenotype through a specific program. EMT is closely related to hepatocyte dedifferentiation, and its occurrence leads to a sharp decline in crucial liver functions.
[0040] The genes and their encoded proteins involved in this invention include: The CYP1A1 gene (NCBI ID: 1543) belongs to the CYP1A family, just like CYP1A2. Its expression rate is often used in conjunction with CYP1A2 to assess the maturity and differentiation status of hepatocytes.
[0041] The CYP1A2 gene (NCBI ID: 1544) encodes cytochrome P450 1A2 (CYP1A2), an important drug-metabolizing enzyme in the liver that plays a vital protective role in liver damage caused by chemical drugs.
[0042] The CYP3A4 gene (NCBI ID: 1576) encodes cytochrome P450 3A4 (CYP3A4, UniProt ID: P08684), which is the most abundant CYP enzyme expressed in the liver, accounting for approximately 30%–40% of the total CYP enzyme content in the liver.
[0043] The ALB gene (NCBI ID: 213, UniProt ID: P02768) encodes serum albumin, a protein expressed only in the liver and reflecting the synthetic function of hepatocytes.
[0044] The AAT gene (NCBI ID: 5265, UniProt ID: P01009) encodes α1-antitrypsin (AAT), a protein mainly synthesized by the liver and released into the bloodstream. It is a serine protease inhibitor and the most abundant protease inhibitor in the bloodstream. It participates in maintaining the protease / antiprotease balance in lung and liver tissues and has important anti-inflammatory and immunomodulatory functions.
[0045] The CPS1 gene (NCBI ID: 1373, UniProt ID: P31327) encodes carbamoyl phosphate synthase 1 (CPS1), a multidomain enzyme protein found in the mitochondria of the liver. Under physiological conditions, CPS1 is a liver-specific protein that primarily catalyzes the first step of the urea cycle and is a key enzyme in the liver's removal of ammonia, a metabolic waste product.
[0046] The Vimentin gene (NCBI ID: 7431, UniProt ID: P08670) encodes vimentin, an intermediate fibrous protein primarily found in mesenchymal cells. Vimentin is typically not expressed in normal hepatocytes, but it is overexpressed in epithelial-derived malignant tumor cells such as hepatocellular carcinoma. It plays a crucial role in the development and progression of liver cancer by directly interacting with carcinogenic factors and regulating processes such as epithelial-mesenchymal transition (EMT).
[0047] The GAPDH gene (NCBI ID: 2597, UniProt ID: P04406) encodes glyceraldehyde-3-phosphate dehydrogenase (GAPDH). This gene has a highly conserved sequence, and the enzyme it encodes is a product of the housekeeping gene. It is expressed at high levels in almost all tissues, and the protein expression level is usually constant in the same type of cells or tissues.
[0048] The HNF4α gene (NCBI ID: 3172, UniProt ID: P41235) encodes hepatocyte nuclear factor 4α (HNF4α), a transcription factor that plays a central role in the liver. HNF4α is a master regulator of liver differentiation, regulating a large number of genes related to hepatocyte-specific functions, including those related to drug-metabolizing enzymes, glucose and lipid metabolism, and the urea cycle.
[0049] The Ki67 gene (NCBI ID: 4288, UniProt ID: P46013) encodes the nuclear proliferation antigen Ki67, which is highly expressed in dividing cells but not in resting cells. It is a widely used cell proliferation marker in clinical practice.
[0050] It should be noted that the mass-volume ratio concentrations mentioned in this invention are all expressed in g / mL, i.e., w / v, where g represents the mass of the corresponding component and mL represents the volume of the solution; the mass-volume ratio concentration represents the mass of the corresponding component contained in each mL of solution, expressed in g.
[0051] In this invention, the volume ratio concentration is expressed as v / v, that is, the content of the corresponding component in the mixture is expressed as a volume ratio, wherein the first "v" represents the volume of the corresponding component, and the second "v" represents the total volume of the resulting solution or mixture; the volume ratio concentration represents the volume proportion of the corresponding component contained in each unit volume of solution or mixture.
[0052] B27 contains various hormones and antioxidants, which are used to support cell survival and maintain specific lineage phenotypes in serum-free culture systems. Among them, B27minus insulin is a B27 compound additive that does not contain insulin.
[0053] GlutaMax is a stable L-glutamine dipeptide derivative, specifically L-alanyl-L-glutamine.
[0054] Activin A is a superfamily regulator of transforming growth factor-β (TGF-β) that activates the Smad2 / 3 signaling pathway to induce pluripotent stem cells to differentiate toward a specific endoderm.
[0055] Wnt3a is an activator of the Wnt signaling pathway, used to promote the self-renewal of stem cells or to induce differentiation toward the mesoderm / endoderm in specific differentiation systems.
[0056] KGF is keratinocyte growth factor, which is used to specifically promote the proliferation, migration and maturation of epithelial lineage cells in the mid-to-late stages of differentiation.
[0057] NEAA is a mixture of non-essential amino acids used as a metabolic co-substrate to reduce the cellular's own anabolic burden and enhance the overall cell viability within the culture system.
[0058] Vitamin C is an antioxidant or its stable derivatives, used to scavenge free radicals in the system, promote collagen matrix synthesis, and improve cell reprogramming or differentiation efficiency of specific lineages.
[0059] FGF2 is a fibroblast growth factor used to maintain the undifferentiated state and pluripotency of pluripotent stem cells, or to promote the proliferation of precursor cells.
[0060] BMP4 is a bone morphogenetic protein receptor activator that, by activating the Smad1 / 5 / 8 pathway, is used to quantitatively induce stem cells to differentiate into mesoderm, ectoderm, or trophoblast.
[0061] ITE is a small molecule agonist of the endogenous aryl hydrocarbon receptor (AhR).
[0062] SR12813 is a small molecule agonist of the pregnane X receptor (PXR), which can induce or regulate stem cell differentiation by activating PXR and mediating the signal transduction network between nuclear receptors.
[0063] DAPT is a γ-secretase inhibitor that acts as a blocker of the Notch signaling pathway, used to relieve Notch-mediated lineage lateral inhibition and promote directed cell maturation.
[0064] Forskolin is an adenylate cyclase activator that promotes the directed evolution of precursor cells into functional mature cells by upregulating intracellular cyclic adenosine monophosphate (cAMP) levels.
[0065] The invention has now been generally described, and will be more readily understood by referring to the following embodiments, which are provided by way of example and not by way of limitation.
[0066] The RPMI 1640 medium used in this embodiment of the invention was purchased from Gibco (catalog number: 11875093); BM medium: IMDM medium and Advanced DMEM / F-12 were mixed at a 1:1 (v / v) ratio, and then 1% (v / v) penicillin-streptomycin antibiotics, 1% (v / v) Chemically Defined Lipid Concentrate, 450 μM 1-thioglycerol, and 15 μg / mL transferrin were added according to the volume ratio of the basal mixed medium. Specifically, IMDM (Gibco, 12440053), Advanced F12 (Gibco, 12634028), GlutaMAX (Gibco, 35050061), penicillin-streptomycin antibiotics (Gibco, 15640055), and Chemically Defined Lipid Concentrate (Pronosai) were used. PB180643, 1-thioglycerol (MCE, HY-W010572), transferrin (Sigma, T1147); ITE was purchased from MCE (catalog number HY-19317, purity: 99.27%); SR12813 was purchased from MCE (catalog number HY-100793, purity: 99.84%); IPSC DYR0100 cells were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai), accession number SCSP-1301; gelatin was purchased from Sinopharm Chemical Reagent Co., Ltd. (catalog number 10010328); sodium alginate was purchased from Sinopharm Chemical Reagent Co., Ltd. (catalog number 30164428); hyaluronic acid was purchased from Maclean's Reagent (catalog number 9067-32-7). Unless otherwise specified, all other biochemical reagents were purchased from conventional commercial channels in this field.
[0067] Example 1 A kit for inducing pluripotent stem cells to differentiate into hepatocytes.
[0068] The kit contains: a composite crystal scaffold assembly and a chemical induction assembly.
[0069] The composite crystalline scaffold assembly is formed by loading a porous material onto a fabric. The porous material is prepared by mixing a molding material and a crosslinking agent. The preparation process of the porous material is as follows: The molding material was dissolved in water to obtain a hyaluronic acid solution with a mass-volume concentration of 2% (g / mL), a sodium alginate solution with a mass-volume concentration of 2% (g / mL), and a gelatin solution with a mass-volume concentration of 2% (g / mL). A premix was obtained by mixing the ingredients in a volume ratio of 1:1:1. Then, crosslinking agents (NHS and EDC) were added to the premix and stirred until homogeneous to obtain a mixed solution. The concentration of NHS in the mixed solution was 2 mg / mL and the concentration of EDC was 4 mg / mL.
[0070] Porous material was cast onto pre-cut hot air cotton and spread evenly with a coating rod. It was then placed in a -20°C freezer for 16 hours to obtain cryocrystalline gel. The cryocrystalline gel was removed and allowed to thaw naturally at room temperature. After thawing, it was rinsed repeatedly with deionized water five times to remove unreacted gelatin, sodium alginate, hyaluronic acid, and crosslinking agent, resulting in pore-in-pore crystalline gel. The pore-in-pore crystalline gel was pre-frozen at -80°C for 5 hours and then placed in a vacuum drying oven and dried at -50°C and 0.07 MPa for 24 hours to obtain a composite crystalline gel scaffold assembly.
[0071] The chemical induction components include an endoderm induction module, a hepatocyte differentiation module, a hepatocyte expansion module, and a hepatocyte maturation induction module, all packaged independently in sequence according to differentiation time.
[0072] The endoderm induction module includes a first culture medium and a second culture medium. The first culture medium is based on RPMI1640 and supplemented with 1% B27 minus insulin (v / v), 1% GlutaMax (v / v) cytokines, 100 ng / mL Activin A, and 50 ng / mL Wnt3a. The second culture medium is based on RPMI1640 and supplemented with 1% Glutamax (v / v), 1% B27 (v / v), 10 μg / mL vitamin C, and 50 ng / mL KGF.
[0073] The hepatoblast differentiation module includes a third culture medium, which is based on RPMI 1640 and supplemented with 1% Glutamax (v / v), 1% B27 (v / v), 1% NEAA (v / v), 10 ng / ml FGF2 and 20 ng / ml BMP4.
[0074] The hepatoblast maturation induction module includes a fourth culture medium containing BM as the basal medium, supplemented with 10 µM dexamethasone, 10 µM DAPT, 10 µM Forskolin, 10 µg / mL insulin, 1 mM ascorbic acid, 0.5 µM ITE, and 1 µM SR12813. BM is composed of IMDM medium and Advanced DMEM / F-12 at a 1:1 (v / v) ratio, and then 1% (v / v) penicillin-streptomycin antibiotics, 1% (v / v) chemically defined lipid concentrate, 450 μM 1-thioglycerol, and 15 μg / mL transferrin are added according to the volume ratio of the basal mixed medium.
[0075] Example 2 ITE and SR12813 synergistically enhance hepatocyte enzyme activity.
[0076] Approximately 1.2 million IPSC DYR0100 cells were uniformly seeded into Matrigel-coated 6-well plates and cultured in mTeSR1 medium containing 10 μM Y-27632. One day after seeding, when cell confluence was approximately 80-90%, differentiation was induced. Differentiation was performed using the kit described in Example 1. Endoderm induction medium RPMI1640 was supplemented with 1% B27 minus insulin (v / v), 1% GlutaMax (v / v) cytokines including 100 ng / mL Activin A and 50 ng / mL Wnt3a for 3 days. After induction, the induction medium was changed to RPMI1640 supplemented with 1% GlutaMax (v / v), 1% B27 (v / v), 10 μg / mL vitamin C, and 50 ng / mL KGF for 2 days.
[0077] After endoderm induction, the supernatant was aspirated and washed twice with PBS. The culture medium was changed to RPMI 1640 with 1% Glutamax (v / v), 1% B27 (v / v), 1% NEAA (v / v), 10 ng / ml FGF2 and 20 ng / ml BMP4 added for 5 days to induce hepatocytes.
[0078] Divide hepatoblasts into five groups, and the composition of the basal medium (BM) in each group is: IMDM medium and Advanced DMEM / F-12 are mixed at 1:1 (v / v), then 1% (v / v) penicillin-streptomycin double antibody, 1% (v / v) Chemically Defined Lipid concentrate, 450 μM 1-thioglycerol, and 15 μg / mL transferrin are added according to the volume ratio of the basal mixed medium. The induction experiment groups are set as follows: Kamiya group: Basal medium BM supplemented with 0.1 µM dexamethasone and 10 ng / ml OSM, induction for 12d; Control group (CON): Basal medium BM supplemented with 10 µM dexamethasone, 10 µM DAPT, 10 µM Forskolin, 10 µg / mL insulin, 1 mM ascorbic acid, induction for 12d; + ITE group: After induction for 9 days with basal medium BM supplemented with 10 µM dexamethasone, 10 µM DAPT, 10 µM Forskolin, 10 µg / mL insulin, 1 mM ascorbic acid, 0.5 µM ITE is added for another 3 days of induction; + SR12813 group: After induction for 9 days with basal medium BM supplemented with 10 µM dexamethasone, 10 µM DAPT, 10 µM Forskolin, 10 µg / mL insulin, 1 mM ascorbic acid, 1 µM SR12813 is added for another 3 days of induction; +ITE+ SR12813 group: After induction for 9 days with basal medium BM supplemented with 10 µM dexamethasone, 10 µM DAPT, 10 µM Forskolin, 10 µg / mL insulin, 1 mM ascorbic acid, 0.5 µM ITE and 1 µM SR12813 are added for another 3 days of induction.
[0079] <CYP450 Enzyme Activity Detection> Use P450-Glo TM Detection kits (Promega, V9002 and V8422) to determine the activities of CYP3A4 and CYP1A2 cellular enzymes in the hepatocyte-like cells of each group described above, and count the number of cells in each well after the determination is completed.
[0080] The results of CYP450 enzyme activity detection are as shown in Figure 1As shown in the figure, it can be seen that the hepatocyte CYP1A2 enzyme activity in the +ITE group is significantly enhanced, and there is no significant difference in CYP1A2 enzyme activity between the +ITE+ SR12813 group and the +ITE group; the hepatocyte CYP3A4 enzyme activity in the +SR12813 group is significantly increased, and meanwhile the hepatocyte CYP3A4 enzyme activity in the +ITE+ SR12813 group is further improved.
[0081] <RT-qPCR detection> Take the hepatocyte-like cells of each group above, extract RNA using SteadyPure RNA Extraction Kit (Accurate Biology, AG21024), and reverse transcribe the RNA sample into cDNA using Reverse Transcription Kit (Accurate Biology, AG11711). Subsequently, after diluting the obtained cDNA 5 times, use the primer pairs CYP1A2 primer F / R, CYP1A1 primer F / R, CYP3A4 primer F / R, and UGT1A1 primer F / R respectively to perform RT-qPCR (SYBR High-Sensitivity qPCR SuperMix, Novoprotein, Cat. No. E099), with the reaction program shown in Table 1. The nucleotide sequences of the above primers are shown in SEQ ID NO: 1 to 8 respectively.
[0082] CYP1A2 primer F (SEQ ID NO:1): AACAAGGGACACAACGCTGAAT; CYP1A2 primer R (SEQ ID NO:2): GGAAGAGAAACAAGGGCTGAGT; CYP1A1 primer F (SEQ ID NO:3): TCCCCCACAGCACAACAAGA; CYP1A1 primer R (SEQ ID NO:4): GCTTGCCCATGCCAAAGATAA; CYP3A4 primer F (SEQ ID NO:5): GGTGGTGAATGAAACGCTCAG; CYP3A4 primer R (SEQ ID NO:6): ACCCCTTTGGGAATGAACATC; UGT1A1 primer F (SEQ ID NO:7): TAAGTGGCTACCCCAAAACG; UGT1A1 primer R (SEQ ID NO:8): GCTTTGCATTGTCCATCTGA.
[0083] Table 1. RT-qPCR reaction program.
[0084]
[0085] RT-qPCR test results are as follows Figure 2 As shown, the expression levels of CYP1A2 and CYP1A1 genes were significantly upregulated in the +ITE group; only the expression level of CYP3A4 gene was significantly upregulated in the +SR12813 group; and the expression levels of CYP1A2, CYP1A1, and CYP3A4 genes in hepatocytes were significantly upregulated in the +ITE+SR12813 group, while no significant difference was found in the UGT1A1 gene. Furthermore, the CYP1A1 and CYP3A4 genes in the +ITE+SR12813 group were also significantly upregulated compared to the +ITE and +SR12813 groups. This indicates that adding ITE and SR12813 can significantly upregulate the expression levels of CYP1A2, CYP1A1, and CYP3A4 genes, and that the combined use of these genes has a more significant effect on enhancing the activity of hepatocyte metabolic enzymes than using any one of them alone.
[0086] Example 3 Research on the selection of porous materials.
[0087] Fabrication of composite crystalline scaffold 1: (1) Fabric cutting: Use clean scissors to cut the hot air cotton into the required shape and size for later use.
[0088] (2) Preparation of mixed solution: Weigh 1g of gelatin (GT) into 100mL of deionized water and stir in a 60℃ water bath until completely dissolved; weigh 1g of sodium alginate (ALG), add 100mL of deionized water and stir at room temperature until completely dissolved. Then mix the above solutions at a volume ratio of 1:1 and stir evenly to obtain a mixed solution of crystal gel precursor.
[0089] (3) Casting: Weigh out the components of the crosslinking agent, NHS and EDC, dissolve them in a small amount of deionized water, and then mix them with the crystal gel precursor mixed solution to make the final concentrations of NHS and EDC 2 mg / mL and 4 mg / mL, respectively. After stirring evenly, immediately cast the mixture onto the cut hot air cotton and spread it evenly with a coating stick.
[0090] (4) Defoaming: Place the sample from step (3) on ice and let it stand for 5 minutes to allow the bubbles to dissipate.
[0091] (5) Freeze-crosslinking reaction: The defoamed precursor liquid-hot air cotton mixture was placed in a low temperature freezer at -20℃ and frozen-crosslinked for 16h to obtain freeze crystal gel.
[0092] (6) Thawing and purification: The frozen crystal gel was allowed to thaw naturally at room temperature. After thawing, it was rinsed repeatedly with deionized water 5 times to obtain the pore-in-pore crystal gel.
[0093] (7) Post-processing: The crystalline adhesive in the hole is pre-frozen in a -80℃ refrigerator for 5 hours, and then placed in a vacuum drying oven and dried at -50℃ and 0.07MPa for 24 hours to obtain the finished composite crystalline adhesive scaffold.
[0094] Preparation of composite crystal scaffold 2: The preparation method is the same as that of composite crystal scaffold 1, except that the 1% (w / v) sodium alginate solution is replaced with a 1% (w / v) hyaluronic acid solution.
[0095] Preparation of composite crystal scaffold 3: The preparation method is the same as that of composite crystal scaffold 1, except that 1% (w / v) of hyaluronic acid solution is added.
[0096] Preparation of composite crystal scaffold 4: The preparation method is the same as that of composite crystal scaffold 1, except that 1% (w / v) sodium alginate solution is replaced with 2% (w / v) chitosan solution.
[0097] Propidium iodide staining results showed that cells cultured on scaffold 1 and scaffold 2 exhibited significantly more red fluorescence (e.g., ...). Figure 3 and Figure 4 As shown in the figure), the combination of components of scaffold 1 and scaffold 2 leads to more apoptosis events and affects cell viability, while scaffold 3 and scaffold 4 show significantly less red fluorescence (as shown in the figure). Figure 5 and Figure 6 As shown in the image, the live cells (green) are widely and evenly distributed within the scaffold or its interior, with clearly defined and extended morphologies. This indicates that the cells have good affinity and adhesion to scaffolds 3 and 4. Furthermore, Figure 5 In the middle, stent 3 is relative to stent 4 ( Figure 6 The cells formed relatively compact spheroids, which were relatively uniform in size and of suitable dimensions; Figure 6 It can be seen that replacing sodium alginate and hyaluronic acid with chitosan prevents hepatocytes from forming spheroids. In summary, gelatin, sodium alginate, and hyaluronic acid can work together to promote cell self-assembly into spheroids, thereby promoting three-dimensional spheroid growth.
[0098] Figure 7 The image shown is a scanning electron microscope image of scaffold 3, revealing a fiber-porous membrane composite interwoven structure that combines the mechanical support of a fiber network with the high specific surface area of a porous membrane.
[0099] Example 4 This embodiment provides a method for in vitro induction of pluripotent stem cell differentiation into hepatocytes, including the following steps: Step 1: Preparation of composite crystalline scaffold (1) Fabric cutting: Use clean scissors to cut the hot air cotton into the required shape and size for later use.
[0100] (2) Preparation of mixed solutions: Weigh 2g of gelatin into 100mL of deionized water and stir in a 60℃ water bath until completely dissolved; weigh 2g of sodium alginate, add 100mL of deionized water and stir at room temperature until completely dissolved; weigh 2g of sodium hyaluronate, add 100mL of deionized water and stir at room temperature until completely dissolved. Then, mix the above solutions in a volume ratio of 1:1:1 and stir evenly to obtain a mixed solution of crystal gel precursor.
[0101] (3) Casting: Weigh the crosslinking agents NHS and EDC, dissolve them in a small amount of deionized water, and then mix them with the crystal gel precursor mixed solution to make the final concentrations of NHS and EDC 2 mg / mL and 4 mg / mL, respectively. After stirring evenly, immediately cast the mixture onto the cut hot air cotton and spread it evenly with a coating stick.
[0102] (4) Defoaming: Place the sample from step (3) on ice and let it stand for 5 minutes to allow the bubbles to dissipate.
[0103] (5) Freeze-crosslinking reaction: The defoamed precursor liquid-hot air cotton mixture was placed in a low temperature freezer at -20℃ and frozen-crosslinked for 16h to obtain freeze crystal gel.
[0104] (6) Thawing and purification: The frozen crystal gel was allowed to thaw naturally at room temperature. After thawing, it was rinsed repeatedly with deionized water 5 times to obtain the pore-in-pore crystal gel.
[0105] (7) Post-processing: The crystalline adhesive in the hole is pre-frozen in a -80℃ refrigerator for 5 hours, and then placed in a vacuum drying oven and dried at -50℃ and 0.07MPa for 24 hours to obtain the finished composite crystalline adhesive scaffold.
[0106] Step 2, Cell Seeding Hepatocytes passaged and cultured in Example 1 were used to dissociate the cells from the plastic dish into a single-cell suspension using Accutase, and the concentration was adjusted to 1×10⁻⁶ using the fourth culture medium. 7 ~4×10 7 Cells / mL. Subsequently, 80 μL of single-cell suspension was seeded onto each composite crystalloid scaffold (3 cm in diameter), placed on the culture plate lid to adhere to it, and incubated upside down in a 37°C, 5% CO2 incubator for 2 hours. The composite crystalloid scaffolds were then flipped over and incubated upside down for another 4 hours. The composite crystalloid scaffolds were then removed and placed in the culture plate, and fourth medium was added until submerged. The fourth medium was changed daily for a 12-day culture period. Specifically, the basal medium BM was induced for 9 days with the addition of 10 µM dexamethasone, 10 µM DAPT, 10 µM Forskolin, 10 µg / mL insulin, and 1 mM ascorbic acid, followed by 3 days of induction with the addition of 0.5 µM ITE and 1 µM MSR12813.
[0107] <Detection of Hepatocyte Growth Morphology and Activity> Take the composite gel scaffold from which the cells were seeded, and use Beyo3D... TM The Calcein / PI staining kit (Beyotime, C1371S) was used to analyze the viability of hepatocyte spheres on a scaffold. After incubation at 37°C for 15 min, the stained cells were observed and photographed under a fluorescence microscope.
[0108] Staining results as follows Figure 8 As shown, cell viability staining revealed that most cells exhibited green fluorescence, indicating ideal cell viability; only a small number of cells showed red fluorescence, indicating cell death. The cells exhibited a clustering and spherical growth pattern, with relatively uniform cell spheroid size. This indicates that the hepatocyte spheroids grew well on the composite cell scaffold. Spherical growth demonstrates significant advantages in simulating tissue complexity and physiological function, forming three-dimensional (3D) cell aggregates that more closely resemble the actual structure and intercellular interactions of in vivo tissues. Furthermore, the hepatocyte spheroids better maintained their phenotype and function during in vitro culture.
[0109] Comparative Example 1 Hepatocytes were prepared using a traditional two-dimensional planar culture method.
[0110] It is basically the same as Example 4, except that the "composite crystal scaffold" is replaced with "commercial matrix adhesive".
[0111] Comparative Example 2 IPSC DYR0100 cells.
[0112] <Comparison of Hepatocyte Gene and Protein Expression> After the induction of mature liver-like cells in Example 4 and Comparative Example 1 was completed, the supernatant was aspirated, and the cells were washed once with 1×PBS, and the waste liquid was aspirated again. An appropriate amount of RIPA tissue / cell lysis buffer (containing PMSF) was added as needed, and the cells were scraped off using a cell scraper. The cell suspension was transferred to a 2mL centrifuge tube, and the cells were lysed on ice using an ultrasonic homogenizer. The cells were centrifuged at 12000g for 10 minutes at 4°C. The supernatant was then transferred to a 1.5mL centrifuge tube. The protein concentration of the samples was detected using a BCA protein concentration assay kit, and each sample was diluted to the same concentration using RIPA tissue / cell lysis buffer (containing PMSF) according to the measured protein concentration. 5× protein loading buffer was added, mixed well, and placed in 100°C hot water for 5 minutes. The mixture was then stored at -80°C for later use.
[0113] Western Blot Procedure: SDS-PAGE Protein Electrophoresis: Place the prepared protein gel into the electrophoresis tank and pour in SDS-PAGE running buffer; remove the comb and add protein sample and three-color pre-stained protein marker to each well; electrophoresis voltage is 90V→120V; Transfer: Cut the required portion of the protein gel for transfer; transfer voltage is 100V, adjust the transfer time according to the protein size; Blocking: Block with 1×TBST solution containing 5% skim milk powder at room temperature for at least 1 hour; Primary Antibody Incubation: Aspirate the waste liquid and add 5 mL of the corresponding primary antibody diluted with TBST solution containing 5% skim milk powder; Secondary Antibody Incubation: Recover the primary antibody, wash three times with TBST, incubate with secondary antibody at 37°C for 1 hour, recover the secondary antibody after incubation, wash the membrane, and develop with ultrasensitive luminescent buffer. The primary antibodies used in this step are shown in Table 2.
[0114] Table 2. WB primary antibody catalog number and dilution ratio.
[0115]
[0116] Protein immunoblotting results as follows Figure 9 As shown, compared to cells cultured in two-dimensional planar environments, hepatocytes on composite crystalloid scaffolds exhibit upregulated secretory protein ALB, ammonia metabolism-related enzyme CPS1, and phase I metabolic enzyme CYP3A4, indicating a significant increase in the expression levels of functional proteins in hepatocytes cultured in three dimensions. Furthermore, hepatocytes express Vimentin (an EMT marker protein) in 2D culture, but its expression level generally shows a downward trend after conversion to 3D culture. This reflects the significant impact of cell culture dimensions on hepatocyte phenotype (such as the epithelial-mesenchymal transition state).
[0117] <Comparison of Cell Immunofluorescence> After the induction of mature hepatoid cells in Comparative Example 1 was completed, the culture medium was discarded, the cells were washed once with PBS, then fixed with 4% paraformaldehyde at room temperature for 20 minutes, washed three times with PBS, permeabilized with 0.5% Triton X-100 for 20 minutes, washed three times with PBS, and then blocked with goat serum for 30 minutes. Subsequently, diluted primary antibody solution was added, and the cells were incubated overnight at 4 degrees Celsius. The next day, the primary antibody was recovered, the cells were washed twice with PBS, diluted fluorescent secondary antibody was added, and the cells were incubated at room temperature for 1 hour. After washing three times with PBS, the cell nuclei were stained with DAPI for 5 minutes, followed by washing with PBS and adding an anti-fluorescence quencher. The cells were then observed and photographed under a fluorescence microscope.
[0118] After the induction of mature hepatoid cells in Example 4 was completed, the composite crystal gel material was removed from the well plate, the culture medium was washed, and after washing twice with PBS, it was fixed with 4% paraformaldehyde at room temperature for 20 minutes. After washing three times with PBS, it was permeabilized with 0.5% Triton X-100 for 30 minutes. After washing three times with PBS, it was blocked and incubated with goat serum for 30 minutes. Then, the diluted primary antibody was added and incubated overnight at 4 degrees Celsius. The next day, the primary antibody was recovered, washed twice with PBS, and diluted fluorescent secondary antibody was added and incubated at room temperature for 1 hour. After washing three times with PBS, the cell nuclei were stained with DAPI for 5 minutes. After washing with PBS, an anti-fluorescence quencher was added, and the cells were observed and photographed under a fluorescence microscope.
[0119] The primary antibodies used are shown in Table 3.
[0120] Table 3. Immunofluorescence primary antibody catalog number and dilution ratio
[0121] The results are as follows Figures 10-15 As shown, consistent with the results of the Western blot (WB) experiment, compared with 2D monolayer culture, the composite crystalloid scaffold induced the expression of various genes in hepatocyte spheres as follows: ALB , AAT , CPS1 , CYP1A2 , ARG1 , HNF4A , CYP3A4 Upregulation, and EMT-related genes Vimentin Downregulation of expression. These results indicate that the three-dimensional crystalloid scaffold promotes the expression of genes related to hepatoid cells in HLC and can reduce... Vimentin Expression, hepatoid cells develop into a more mature differentiated state, Vimentin Downregulation indicates that cells are maintaining epithelial properties or returning from a mesenchymal state to an epithelial state, restoring tight junctions between cells and reducing cell mobility.
[0122] Clearly, three-dimensional scaffold culture provides hepatocytes with a microenvironment closer to their physiological state by mimicking the physical support of the extracellular matrix and the three-dimensional interactions between cells in vivo. This inhibits the EMT process, more effectively upregulates liver function genes, establishes and maintains cell polarity, and enhances the expression levels of key metabolic enzymes and secreted proteins. Immunofluorescence results showed significant differences in cytoskeleton remodeling and polarity differentiation when hepatocytes transformed from a flat 2D cell monolayer to spherical 3D cell spheres within a crystalloid scaffold. The disappearance and downregulation of vimentin expression in hepatocyte spheres were observed, and its downregulation is a marker for the restoration of epithelial polarity, the establishment of tight junctions, and the formation of dense tissue structures.
[0123] Furthermore, by introducing a composite crystalloid scaffold to construct a biomimetic three-dimensional microenvironment at the hepatocyte stage, and combining it with a maturation induction system containing specific small molecules ITE and SR12813, the temporal regulation of hepatocyte microenvironment remodeling and functional maturation was achieved. This resulted in induced hepatocytes possessing both high maturity, strong drug metabolism capacity, and a stable epithelial phenotype. ALB , HNF4A and CYP3A4 Expression of mature functional markers was significantly increased, and EMT-related genes were also significantly increased. Vimentin The expression is reduced, thereby obtaining induced hepatocytes that more closely resemble the biological characteristics of natural mature hepatocytes.
[0124] For any points not covered above, existing technologies shall apply.
[0125] Although specific embodiments of the present invention have been described in detail by way of examples, those skilled in the art should understand that the above examples are for illustrative purposes only and are not intended to limit the scope of the invention. Those skilled in the art can make various modifications or additions to the described specific embodiments or use similar methods to replace them, without departing from the direction of the invention or exceeding the scope defined by the appended claims. Those skilled in the art should understand that any modifications, equivalent substitutions, improvements, etc., made to the above embodiments based on the technical essence of the present invention should be included within the protection scope of the present invention.
Claims
1. A kit for inducing pluripotent stem cells to differentiate into hepatocytes, characterized in that, The kit contains: A composite crystal scaffold assembly is used to provide a porous framework for the attachment and growth of hepatocytes. The porous material is cast onto a fabric, and after a freeze cross-linking reaction, an ice crystal template is formed. The ice crystal template is then removed by freeze drying. The fabric has a pore size of 1~500 µm and a thickness of 0.5~3 mm. The preparation process of the porous material is as follows: The molding materials were dissolved in water to obtain hyaluronic acid solution, sodium alginate solution, and gelatin solution with a mass-volume concentration of 1% to 3%; A premixed solution was obtained by mixing the ingredients in a preset volume ratio of 1:(0.5~1.5):(0.5~1.5). Then, a crosslinking agent was added to the premixed solution and stirred until homogeneous to obtain a mixed solution with a total solid content of 0.5%~20.0%, which is the porous material. The crosslinking agent is a mixture of NHS and EDC. The chemical induction assembly comprises the following modules, packaged independently in sequence according to differentiation time: Endoderm induction module, used to induce pluripotent stem cells into endoderm cells; The hepatoblast differentiation module is used to differentiate endoderm cells into hepatoblasts; A hepatoblast maturation induction module for differentiating hepatoblasts into mature hepatocytes, the hepatoblast maturation induction module comprising small molecule ITE and SR12813; The composite crystal scaffold assembly is used in conjunction with the hepatoblast maturation induction module to seed the hepatoblasts into the composite crystal scaffold assembly, which provides three-dimensional support for the hepatoblasts.
2. The reagent kit according to claim 1, characterized in that, The endoderm induction module includes a first culture medium and a second culture medium; the first culture medium contains a first basal culture medium, B27 minus insulin, GlutaMax, Activin A, and Wnt3a; the second culture medium contains a second basal culture medium, GlutaMax, B27, vitamin C, and KGF. The hepatoblast differentiation module includes a third culture medium, which contains a third basal culture medium, Glutamax, B27, NEAA, FGF2 and BMP4. The hepatocyte maturation induction module includes a fourth culture medium containing hepatocyte basal medium, dexamethasone, DAPT, Forskolin, insulin, ascorbic acid, ITE, and SR12813.
3. The reagent kit according to claim 2, characterized in that, The concentration of ITE in the fourth culture medium is 0.2~0.6 µM, and the concentration of SR12813 is 0.5~1.2 µM.
4. The reagent kit according to claim 2, characterized in that, The first basal culture medium, the second basal culture medium and the third basal culture medium are all at least one of DMEM high glucose, DMEM-F12 and RPMI1640 culture medium.
5. The reagent kit according to claim 1, characterized in that, The concentration of NHS in the mixed solution is 1 mg / mL to 2 mg / mL, and the concentration of EDC is 3 mg / mL to 4 mg / mL.
6. The reagent kit according to claim 1, characterized in that, The fabric is one of the following: non-cytotoxic needle-punched cotton, non-woven fabric, and hot-air cotton.
7. The kit according to claim 1, characterized in that, The reaction temperature of the freeze-crosslinking reaction is -25℃ to -10℃, and the reaction time is 12~48 h; the vacuum degree of the freeze-drying is 0.06~0.08 MPa, the cold trap temperature is -60℃ to -40℃, and the drying time is 8~48 h.
8. Use of the kit according to any one of claims 1-7 in the preparation of hepatocyte organoid products.
9. A method for inducing pluripotent stem cells to differentiate into hepatocytes in vitro, characterized in that, Includes the following steps: Pluripotent stem cells are cultured in the first culture medium of claim 2 for 2.5 to 3.5 days and in the second culture medium of claim 2 for 1.5 to 2.5 days to obtain endoderm cells; Hepatocytes were obtained by culturing endoderm cells in the third culture medium described in claim 2 for 4.5 to 5.5 days. Hepatocytes were seeded onto the composite crystalloid scaffold assembly described in claim 1 and cultured in the fourth culture medium described in claim 3 for 11-13 days to obtain mature hepatocytes.
10. The use of hepatocytes obtained by the method for in vitro induction of pluripotent stem cell differentiation into hepatocytes as described in claim 9 in the preparation of hepatocyte transplantation products, bioartificial livers, or microencapsulated hepatocyte preparations.
